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Abstract
Background
The recent development of novel Polymerase Chain Reaction (PCR) technologies that confer
theoretical advantages over quantitative PCR has considerable potential in the diagnosis of
low load infections, such as Trypanosoma cruzi in the chronic phase of Chagas disease. We
evaluated the utility of the digital droplet (dd)PCR platform in the detection of T. cruzi infection.
Methodology/Principal findings
We imported a validated qPCR assay targeting the T. cruzi satellite tandem repeat (TcSTR)
region to the ddPCR platform. Following optimization, we tested and repeated a standard curve
of TcI epimastigotes to characterise the analytical performance of the assay on the ddPCR plat-
form. We compared this to published qPCR performance data, and the performance of the
qPCR assay in our own testing. We subsequently tested a panel of 192 previously character-
ized DNA specimens, extracted from the blood of individuals with and without T. cruzi infection.
The assay performed well on the ddPCR platform, showing a limit of detection of 5 copies/μL or
1 parasite/mL. This was higher than the published limit of detection for qPCR, which was 0.46
parasites/mL. The ddPCR platform was not significantly more accurate than qPCR at any con-
centration tested. However, the clinical sensitivity and specificity of the assay were both 100%
with perfect agreement between qPCR and ddPCR positive and negative result calling in clini-
cal specimens. An average of 9,286 copies of TcSTR were detected per parasite.
Conclusions/Significance
The use of the ddPCR platform to run this assay was comparable, but not superior in terms
of performance, to the qPCR platform.
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Author summary
Chagas disease is a complex pathology caused by the parasite Trypanosoma cruzi. This dis-
ease affects more than 8 million people in Latin America and is considered a serious pub-
lic health problem. The diagnosis of the disease is challenging due to the natural course of
infection and therefore molecular tools such as qPCR have been deployed to detect para-
site DNA in infected individuals. However, qPCR is not suitable for diagnosis in the
chronic phase of the disease and new diagnostic tools are needed. Digital droplet (dd)PCR
is a next-generation PCR technology that enables the absolute quantitation of nucleic
acids. This technology has been successfully applied as a diagnostic tool in bacteria and
viruses, but few reports exist for parasites. Herein, we imported a previously validated
qPCR assay to the ddPCR platform. Our results show complete agreement in terms of
diagnostic operative features but a higher limit of detection. Overall, ddPCR did not offer
significant diagnostic benefits compared with qPCR.
Introduction
Chagas disease, caused by Trypanosoma cruzi, is a complex chronic pathology that affects
around 8 million people worldwide and represents a serious public health problem [1]. T.
cruzi parasites exhibit tremendous within-species genetic diversity and have been subdivided
by international consensus into at least six discrete typing units (DTUs) from TcI to TcVI [2,
3]. The acute phase of the disease is usually characterized by mild fever, but in a small propor-
tion of cases, it can be accompanied by myocarditis and other lethal complications [4]. Most
patients continue into the chronic phase, which can be asymptomatic, but about 30% of the
infected patients will develop heart or digestive complications after several years [5].
The diagnosis of Chagas disease is challenging. In the acute phase of infection and disease,
the parasitic load is sufficiently high that direct methods of parasitological observation such as
a blood smear and hematocrit are recommended to diagnose the disease [6–8]. By contrast,
the chronic phase is characterized by a low and intermittent parasitic load that is not likely to
be detected using direct parasitological methods. Therefore, serological assays such as indirect
immunofluorescence assays, indirect hemagglutination test and enzyme linked immunosor-
bent assays (ELISA) are recommended to diagnose the disease [9–12]. Molecular methods
have been developed and currently, there are several real-time quantitative PCR assays that are
commonly used internationally to detect and quantify T. cruzi DNA in blood samples of acute
and chronic Chagas disease patients [13–15]. The evaluation of a number of different genetic
sequences suggested a tandem repeat satellite DNA (TcSTR) sequence of 188 bp that is contin-
uously repeated across the genome of T. cruzi to be an appropriate qPCR target for optimal
sensitivity and specificity [14].
The operating characteristics of molecular tests for detecting T. cruzi DNA have varied
according to clinical phase and technical specifications. The sensitivity for identifying chronic
infection of end-point PCR has ranged between 22% and 75% [9, 16] and in both cases speci-
ficity has estimated at 100%. By contrast, for quantitative PCR (qPCR), sensitivity has ranged
between 60% and 80% for the chronic phase and between 88% and 100% for the acute phase of
infection [6, 14]. Recently, a loop-mediated isothermal amplification assay (LAMP) was
reported that was able to detect T. cruzi DNA in peripheral blood samples collected from well-
characterised seropositive patients, including acute, congenital, chronic and reactivated Cha-
gas disease [17, 18]. The sensitivity of qPCR in the acute phase makes it ideal for the detection
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of such infections; however, the low levels or absence of circulating parasites in chronic cases
means that the sensitivity of this assay is currently too low to allow for proactive screening for
patients with chronic infection. The development of an assay with better performance at low
concentrations may therefore enable the improved detection of infection in chronic Chagas
disease cases, which may support case findings and monitoring.
Digital droplet PCR (ddPCR) is a next-generation PCR technology that enables the absolute
quantitation of nucleic acids by separating a reaction into ~20,000 compartments (droplets)
and using the proportion of fluorescent droplets to indicate target occupancy and positivity.
By isolating the PCR reaction into compartments, the relative concentration of targets, primers
and probes is high, and of inhibitors is low, thereby theoretically allowing improved precision
at lower concentrations and an improved analytical limit of detection compared with qPCR.
Additionally, ddPCR measures the response to the number of copies present in a linear man-
ner thereby allowing smaller differences in load to be accurately quantified, compared with
qPCR that measures logarithmic increases in the target number. The theoretical benefits of
this technology have encouraged its evaluation in the detection of pathogens [19]. While
ddPCR has been evaluated for the detection of bacteria and viruses (for example, Chlamydia
trachomatis, Salmonella, Escherichia coli, Campylobacter jejuni, cytomegalovirus and HIV)
[20–24], few investigations have been conducted into the role of ddPCR in the detection of
protozoan infections. ddPCR assays have been initiated for Schistosoma, Cryptosporidium and
Plasmodium [25–27]. Therefore, the aim of this work was to import a validated international
consensus qPCR assay targeting the TcSTR [14] to the ddPCR platform and compare its ana-
lytical and diagnostic performance with the qPCR iteration to determine whether the technol-
ogy may be useful.
Methods
Ethical statement
The study protocol was approved by the Technical Research Committee and Ethics Research
Board at the National Health Institute in Bogota´, Colombia, protocol CTIN-023-17 in the
framework of the project “Fortalecimiento y vigilancia de la capacidad diagno´stica de enferme-
dades emergentes y reemergentes en Colombia”. Participation (adults only) was voluntary and
patients were asked for informed written consent. The diagnostic evaluation protocol was
additionally approved by the London School of Hygiene & Tropical Medicine Observational
Ethics Committee (protocol number 15515).
Preparation of standard curves for T. cruzi
T. cruzi parasites of TcI (MHOM/CO/04/MG) and TcII (MHOM/BR/53/Y) from different
life-cycle stages were grown (epimastigotes and metacyclic trypomastigotes) in culture as
reported elsewhere [28]. Cultures were aliquoted in the exponential growth stage. A Neubauer
chamber was used to assess the concentration of parasites per mL. Then, 300 μL of the counted
parasites were subjected to DNA extraction using the High Pure PCR Template Roche kit as
reported elsewhere [29], and the DNA was eluted in 100 μL of H2O or TE buffer.
qPCR for T. cruzi
The satellite tandem repeat of T. cruzi (TcSTR) was selected due to its high copy number in the
genome and its routine usage as a diagnostic target for T. cruzi infection. The TcSTR region
can be repeated up to 105 times in the genome and can account for as much as 10% of the
genetic material, although this varies between DTUs. The qPCR described by Ramirez et al.
T. cruzi DNA detection by ddPCR
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was considered an appropriate comparator for this study due to the availability of detailed
evaluation data of analytical and diagnostic performance [14]. For this study, qPCR was con-
ducted using published methodology. The standard curve for TcI epimastigote parasite mate-
rial was determined with the qPCR assay on a single plate using five technical replicates.
ddPCR assay preparation
The TcSTR sequences from Ramirez et al. [14] were used in this study. An endogenous control
assay (Homo sapiens ribonuclease P/MRP subunit p30 [HsRPP30] as described by Luo et al.
2005 [30]) was also added to the test to enable users to check that specimen collection and sam-
ple processing had been completed successfully (Table 1). Both TcSTR and HsRPP30 assays
were run in duplicate in a single well. The ddPCR reaction mixtures (20 μL volume) contained
final concentrations of 1× ddPCR Supermix (Bio-Rad, Hemel Hempstead, UK), 0.9 μM for
each primer and 0.2 μM for probes, and 5 μL of purified sample DNA (Table 1). Droplet gener-
ation and droplet reading for ddPCR were carried out using the Bio-Rad QX100 workflow
according to the manufacturer’s instructions. The first thermal cycling profile tested was
matched to the published qPCR protocol (95˚C for 10 minutes followed by 45 cycles of 95˚C
for 15 seconds and 60˚C for 30 seconds). However, under these cycling conditions for ddPCR,
the primer–probe set yielded poor separation between positive and negative droplet popula-
tions. Based on the results of a systematic assessment of parameters to improve ddPCR perfor-
mance [31], the dissociation and annealing/extension steps in the thermocycling conditions
were extended to 30 seconds and 2 minutes, respectively, and the number of cycles was
increased to 50.
ddPCR data processing
Raw ddPCR data were collected using Quantalife software (Bio-Rad) and were then exported
for analysis using R scripts as reported elsewhere [20]. Thresholds between positive and nega-
tive droplet populations were set manually using per-plate positive and no-template controls
as a guide; for the TcSTR assay, droplets with an amplitude above 3,000 were considered posi-
tive. The Poisson calculation was used to estimate the number of copies/μL of the reaction and
confidence intervals [32]. For classification purposes, we followed the method described by
Roberts et al. to optimize sensitivity and specificity [20]. We used the estimated mean concen-
tration of the target and its standard deviation to define the cumulative distribution function
(c.d.f.) at x = 0. This value describes the probability that the true concentration is less than or
equal to zero copies/μL. The classifier z was defined as 1 − c.d.f. and describes the probability
that the true concentration is greater than zero copies/μL. We excluded samples from further
analysis if the z value for the RPP30 assay was below 0.95. A specimen was considered positive
for ddPCR when the lower 95% confidence interval of the load estimate was above zero, which
is considered to optimize specificity as described by Roberts et al. 2013 [20]. Samples with over
Table 1. Sequences of the primers and probes used in the ddPCR assay.
Primer/probe Sequence 50-30 Reference
cruzi1 ASTCGGCTGATCGTTTTCGA [14]
cruzi2 AATTCCTCCAAGCAGCGGATA [14]
cruzi3 FAM-CACACACTGGACACCAA-MFQB [14]
HsRPP30Fw AGATTTGGACCTGCGAGCG [30]
HsRPP30Rv GAGCGGCTGTCTCCACAAGT [30]
HsRPP30 Probe Hex-TTCTGACCTGAAGGCTCTGCGCG-Qsy-7 [30]
https://doi.org/10.1371/journal.pntd.0007063.t001
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99% droplet occupancy were considered too concentrated for accurate quantitation as they
potentially contravened assumptions of the Poisson distribution. While binary diagnostic clas-
sification is possible, these specimens were retested at a 1 in 100 dilution for quantitation
purposes.
ddPCR assay analytical performance
A standard curve of TcI epimastigote-stage T. cruzi parasites diluted 10-fold from 104–10−3 par-
asites/mL was repeat-tested to assess the reproducibility of the ddPCR test. Each dilution in the
series was tested in five technical replicate wells on a single plate to determine within-assay vari-
ance and then in a single well on five different plates to assess between-plate variability. The ana-
lytical limit of detection was determined as the concentration of the lowest step of this series at
which all 10 replicates tested positive. Due to the known variability in copy number of the
TcSTR region between DTUs [33], we also tested dilution series of TcII parasites to ensure the
assay would not be affected by the differing population genetics of T. cruzi. A dilution series of
the TcI trypomastigote-stage was also tested to ensure that the blood stage of the parasite was
detectable. To estimate the correlation in quantitation between qPCR and ddPCR, the concen-
tration estimates from both platforms were tested using the Pearson correlation coefficient. The
number of TcSTR copies per parasite was determined using ddPCR. The number of parasites
per extraction was 0.3 parasites per mL, as 300 μL of parasite culture was used in the extraction
protocol and downstream analysis. The number of copies per μL in the ddPCR reaction was
also multiplied by four to account for the dilution of DNA in the reaction and was used to quan-
tify the number of TcSTR copies in each dilution point of the standard curve material.
ddPCR diagnostic performance
A total of 192 samples were included in the analysis. Blood samples were collected and stored
in 6 M guanidine hydrochloride and 0.2 M EDTA buffer, pH 8, as described elsewhere [9].
Multiplex qPCR for the detection of satellite DNA of T. cruzi was performed as reported else-
where [34]. The parasitic load was measured by qPCR as parasites per mL according to Mor-
eira et al. 2013 [29]. A total of 106 positive samples that were previously characterized by
qPCR, indirect immunofluorescence assays, an indirect hemagglutination test and ELISA as
positive and 86 negative samples were also characterized by the same techniques.
Our samples included those from patients in the acute phase of infection (n = 11; 10.4%). A
suspected acute case was defined as an individual with>7 days of fever accompanied or not by
hepatomegaly or splenomegaly. A patient was considered to have acute Chagas disease if in
addition to testing positive in parasitological tests (strout, micro-strout, blood thick smear or
hemoculture), positive results were obtained for two serological tests over the course of the fol-
lowing weeks. The average patient age was 49 years (from 5 to 61 years old).
Our samples also included those from patients in the chronic phase of infection (n = 95;
89.6%). These individuals did not fulfil the criteria for acute phase infection but had clinical or
epidemiological suspicion of Chagas disease. The average age of these patients was 49 years
(from 26 to 88 years old). These patients were confirmed as positive for T. cruzi infection
when they tested positive to two serological tests (IFA, ELISA and/or HAI). They were then
classified as chronic undetermined (when no evidence of signs or symptoms of heart compli-
cations were evinced) or chronic determined in all other cases. Among the set of 95 chronic
patients, a total of 30 patients were symptomatic (determined) and the other 65 patients were
asymptomatic (undetermined).
Descriptive analyzes were performed to report the frequencies of infection detected by
qPCR and ddPCR, considering the qualitative result (positive/negative) for each test with
T. cruzi DNA detection by ddPCR
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respect to the total number of samples evaluated (n = 192). The agreement between the results
of the tests was evaluated through the calculation of the coefficient kappa. Sensitivity, specific-
ity and positive and negative predictive values were determined, as indicators of the operative
characteristics of the ddPCR, taking as a reference test the qPCR, previously identified as being
efficient for the detection of infection [14]. A 95% confidence interval (95% CI) using the ana-
lytical method (due to the dichotomous nature of the variables analyzed), was calculated for
the main events of interest. A value of P<0.05 was considered significant. The statistical ana-
lyzes were performed using the software STATA 12.0.
Finally, to test the association between parasitic loads using both platforms (qPCR vs.
ddPCR), a graphic of Bland–Altman was generated using Microsoft Office Excel 2016 soft-
ware. For this, the differences between the loads calculated by ddPCR and qPCR were deter-
mined, and these two values were averaged for each of the samples. Bias was then calculated by
means of the average of the differences for all samples, as well as their respective standard devi-
ations. The upper and lower limits of the deviation were calculated using the bias +/− 1.96
multiplied by the standard deviation. For the statistical tests, normality tests (Shapiro–Wilk)
were initially carried out to determine the distribution of the data. Based on their distribution,
the correlations between age and parasitic loads calculated by each of the evaluated methods
were determined. The differences in the medians of the parasitic loads calculated by each of
the methods, both general and according to the clinical phase and state of the disease were
determined using a Mann–Whitney U test. All statistical analyzes were performed using the
Stata 14 software (StataCorp, 2015. Stata Statistical Software: Release 14. College Station, TX:
StataCorp LP).
Results
ddPCR assay optimisation
The thermal cycling conditions for the TcSTR ddPCR assay were optimized for this study. Fig
1 shows (A) the native assay conditions and (B) the optimised assay conditions across a stan-
dard curve (wells A–G) and one no-template control well (well H). In the diagnostic target
(TcSTR) channel (FAM fluorophore), there was a small increase in the mean negative popula-
tion amplitude under optimized cycling conditions compared with the native cycling condi-
tions (1599 versus 1554, p = 0.01). There was a large increase in mean amplitude of the
positive droplets under the optimized cycling conditions compared with the native ones (8255
versus 5027, p = 0.002). The ratio of positive-to-negative droplet amplitude also increased
from 3.2 to 5.2 (p = 0.002). No-template control wells were negative for both channels under
optimized and native thermocycling conditions. There was no difference in the endogenous
control channel HsRPP30 (HEX fluorophore) negative droplet amplitude between optimised
and native conditions (1161 versus 1146, p = 0.10).
ddPCR analytical performance
During repeat testing of the T. cruzi standard curve, the top standard (104 parasites/mL)
resulted in over 99% of the droplets being saturated. The upper limit of the dynamic range for
accurate quantitation of this assay was 103 parasites/mL. Of 10 repeated readings of the 1 para-
site/mL standard, all 10 were detected. Of 10 repeat readings of the 0.1 parasites/mL standard
(equivalent to approximately 0.5 TcSTR copies/μL or 2.5 TcSTR copies/test), only seven were
detected. The lower dilutions were also not detected in all repeats; therefore, the limit of detec-
tion is 1 parasite/mL, measured as 5 TcSTR copies/μL or 20 TcSTR copies/test. The TcI epi-
mastigotes tested had a mean of 9,286 (range: 8,768–10,113) TcSTR copies per parasite.
T. cruzi DNA detection by ddPCR
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The Pearson correlation coefficient between TcSTR copies/μL and parasites/mL in the
dynamic range of the dilution series was 0.987. The efficiency of the assay was 98% (Fig 2). The
correlation between the qPCR cycle threshold and the ddPCR load estimate was excellent in
the standard curve. Upon testing of different developmental stages and different lineages, both
TcII and TcI trypomastigote curves also performed equally well as the TcI epimastigote curve
(Fig 3).
The ddPCR between-plate coefficient of variation (CV) across the whole series was 101%,
and the CV at 1 parasite/mL was much higher than at 1000 parasites/mL (200% compared
with 53%). The within-plate CV was 13%, and the CV at 1 parasite/mL was much higher than
at 1000 parasites/mL (30% compared with 4%). When comparing the within-plate CV between
Fig 1. Droplet amplitude in the T. cruzi satellite tandem repeat assay on the ddPCR platform for a range of concentrations (wells A–G) and the no-template
control (well H). (A) Assay performed under previously published qPCR thermocycling conditions (40 cycles of 95˚C for 15 seconds and 60˚C for 30 seconds). (B)
Assay performed under optimized conditions (50 cycles of 95˚C for 30 seconds and 60˚C for 120 seconds).
https://doi.org/10.1371/journal.pntd.0007063.g001
T. cruzi DNA detection by ddPCR
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qPCR and ddPCR, the CV of ddPCR across the dilution series did not differ between the plat-
forms (qPCR CV = 18.6% versus ddPCR CV = 13.0%). Also, the ddPCR CV was not signifi-
cantly lower than the CV of qPCR at the lower end of the dilution series (Fig 4).
ddPCR diagnostic performance
The frequency of positives was the same for the two tests being evaluated, at 55.2% [n = 106;
95% CI = 47.9–62.4]. The concordance between the results was absolute (100%) and was sup-
ported by a perfect kappa coefficient (1.0000). Analysis of the operational characteristics of the
ddPCR test revealed great performance (100% in all cases) in detecting T. cruzi DNA
(Table 2), when compared with the results of the qPCR test included as a reference. For all clin-
ical phases and totals there was absolute agreement between the tests. All positive samples
were correctly classified, as were the negative samples. Therefore, all values accurately classified
the samples by clinical stage (100%).
The age of the patients was distributed normally (p = 0.1039), while the load (copies per μL)
found by ddPCR was not distributed normally (p = 0.0000). Spearman correlation coefficient
was determined and there was no correlation between the variables evaluated (age vs. parasitic
load; Spearman’s rho = 0.0012, p = 0.9900), and no correlation was found between the vari-
ables age and copies/μL quantified by qPCR (Spearman’s rho = 0.0727, p = 0.4586). Finally,
when evaluating the differences in median parasitic loads calculated by ddPCR between the
two clinical phases, no statistically significant difference was found (p = 0.8399). Likewise, no
statistically significant differences were found for the median parasitic loads calculated by
Fig 2. Serial 10-fold dilution of TcI epimastigote-stage T. cruzi repeat tested with the T. cruzi satellite tandem repeat assay on the ddPCR platform.
https://doi.org/10.1371/journal.pntd.0007063.g002
T. cruzi DNA detection by ddPCR
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qPCR between the phases (p = 0.9546). When evaluating the association by state with chronic
infection cases, no statistically significant differences were found either by ddPCR or by qPCR
(p = 0.5643 and p = 0.0567, respectively).
A Bland–Altman graph was generated using Microsoft Excel 2016 software. No differences
were observed in quantitation between the techniques when the parasitic loads were low. How-
ever, as the parasitic load increased, differences in the quantification between the two tech-
niques began to become evident since ddPCR underestimates the actual parasitic load (Fig 5).
Discussion
Chagas disease still presents a serious challenge to public health in Latin America and has
increased in profile due to the immigration of infected individuals into non-endemic countries
[35]. One of the challenges in controlling the disease is its diagnosis due to the stark contrast
between the clinical signs of disease and the parasitic load between the acute and chronic
phases of the disease [5]. Parasitological, serological methods and most recently molecular
methods have been deployed to circumvent these challenges [10, 15, 36]. Due to the theoretical
advantages of ddPCR outlined in the introduction, it is an attractive option for the detection
and quantitation of low copy targets.
To optimize the performance of the assay on the ddPCR platform, we extended the number
of cycles to 50 and increased the duration of both the dissociation and annealing/extension
Fig 3. Serial 10-fold dilution of TcII epimastigote-stage and TcI trypomastigote (blood) stage T. cruzi repeat tested with the T. cruzi satellite tandem repeat
assay on the ddPCR platform.
https://doi.org/10.1371/journal.pntd.0007063.g003
T. cruzi DNA detection by ddPCR
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stages of thermocycling. This was successful in that it improved separation between positive
and negative droplets, and vastly improved the ease of setting appropriate thresholds in this
assay. One risk associated with increased cycle number is non-specific amplification, resulting
in a loss in specificity. In this case the increase from 40 to 50 cycles had no effect on analytical
specificity (as evidenced by consistent zero readings during repeat testing of the no-template
control samples) and the excellent clinical specificity of the assay. Cycle number has also been
increased to optimize assays in other contexts, such as the detection of genetically modified
organisms [37], the detection of mutations in AH1N1-infected individuals [38] and the detec-
tion of foodborne pathogens in soft cheese [39]. One limitation of increasing the cycle number
is the concomitant increase in the sample testing time; this may be problematic in high-
throughput settings [31, 40].
Fig 4. Within-plate variance of the T. cruzi satellite tandem repeat assay performed on the qPCR and ddPCR platforms across a range of parasite loads.
https://doi.org/10.1371/journal.pntd.0007063.g004
Table 2. Operative characteristics of the T. cruzi satellite tandem repeat assay performed on the ddPCR platform.
Operative characteristic % 95% confidence interval
Sensitivity 100.0 100.0 100.0
Specificity 100.0 100.0 100.0
Positive predictive value 100.0 100.0 100.0
Negative predictive value 100.0 100.0 100.0
Prevalence 55.2 48.2 62.2
The operative characteristics were determined including qPCR as a reference test [14]
https://doi.org/10.1371/journal.pntd.0007063.t002
T. cruzi DNA detection by ddPCR
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We found the range of accurate quantitation of this assay to be between 100−103 parasites/
mL, equivalent to approximately 5–5000 copies/μL. Typically, this would be considered to be
within acceptable limits of performance for research purposes. The limit of detection of
ddPCR was acceptable, and assay quantitation correlated well with parasitological findings
(Pearson correlation coefficient: 0.987; efficiency: 98%; Fig 2). However, compared with
qPCR, we could not demonstrate the theoretical improvement in precision at low loads that
we expected. The CV was not significantly different between ddPCR and qPCR at any concen-
tration tested [14]. However, it was interesting to observe that the within-plate CV of qPCR
was higher at 1 parasite/mL than at 10 parasites/mL. This might be explained because at low
concentration molecular tests tend to be unstable. This has been already reported for qPCR
[14].
When comparing the limit of detection with that of qPCR, the limit of detection reported
for this assay in the qPCR format was 0.46 parasites/mL [6], whereas in the ddPCR format,
only 7/10 repeats were successfully detected at that level. This has been reported for other path-
ogens, where qPCR has been shown to be more sensitive, e.g. in Cytomegalovirus and Xantho-
monas citri subsp. citri [22, 41]. There are a number of potential reasons for this, many of
which are outlined by Hindson et al. [19]. The assay dynamics could be more suited to the
qPCR well format. Also, the TcSTR is a variable region, as recently demonstrated, and its lack
of stability could affect the sensitivity of a high-resolution test such as ddPCR [42]. One inter-
esting finding was the difference between the dynamic range when testing epimastigotes versus
trypomastigotes. To date, no studies have conducted standard curves with the human-infective
Fig 5. Bland-Altman plot showing the associations of parasitic load between qPCR and ddPCR.
https://doi.org/10.1371/journal.pntd.0007063.g005
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stage of T. cruzi. Our results showed that the standard curve with trypomastigotes showed one
order of magnitude more DNA than epimastigotes (Fig 3). This could be explained by the cell
size of trypomastigotes as they may have double or triple the cell surface of epimastigotes and
subsequently have more DNA content [43]. Also, it might be related to the genomic architec-
ture of T. cruzi as it was recently shown that: i) the DNA transcripts change drastically between
cell stages [44, 45], and ii) trypomastigotes present more telomeres and DNA content than epi-
mastigotes using next generation sequencing [46, 47]. However, these assumptions need to be
validated by conducting more experiments including the testing of metacyclic trypomastigotes
from other DTUs. We are aware that one limitation of our study is that a strict analytical vali-
dation was not conducted as stated in international guidelines for clinical laboratories. How-
ever, this has not been done even for the qPCR or PCR platforms. We used the same pipeline
of validation established for ddPCR platforms already published and it must be kept in mind
that PCR platforms are not currently considered clinical diagnostic tools for Chagas disease.
When evaluating the diagnostic performance of this assay, the concordance between qPCR
and ddPCR was found to be excellent (kappa = 1). With perfect agreement between the positives
and negatives for each of the tests, the operational characteristics showed 100% in all cases
(Table 2). The Bland–Altman plot also showed a good degree of association between the para-
sitic loads for both platforms (Fig 5). Although at high concentration, the ddPCR platform
became saturated and qPCR showed a better performance, explaining the outliers from the
graph. In general, this shows that in this sample set, despite not offering a technical performance
benefit over qPCR, the use of this assay on the ddPCR platform may be as suitable as qPCR for
the detection of T. cruzi. However, one study reported median parasitemia values in chronic
Chagas disease patients from Argentina and Colombia to be 1.93 and 2.31 parasite equivalents/
mL, respectively. Based on our present evaluation, the ddPCR assay should be able to reliably
detect samples with these median loads but may fail on occasion with lower median parasitemia
levels. More concerningly, the median load of parasitemia for Brazilian patients was 0.1 parasite
equivalents/mL, which is below the reproducible limit of detection for the ddPCR assay [29]. A
recent study of patients in the chronic phase showed a sensitivity of 64.2% and specificity of
97.1% for qPCR [6, 48], suggesting it too will not reliably detect all infections in chronic
patients, resulting in a loss of sensitivity. Finally, the cost of ddPCR is known to be approxi-
mately double the price of qPCR, therefore without a significant performance improvement, it
is unlikely that this constitutes a realistic public health surveillance tool. However, the primary
utility of the ddPCR platform on which to run this assay is likely to be as a research tool.
In our study, the ddPCR assay was not efficient at high concentrations of T. cruzi (Fig 1).
This impedes its utility in acute Chagas disease patients, where parasitemia levels tend to be
high and would suggest that DNA samples would need to be diluted prior to application on a
ddPCR platform. A possible solution might be exploring other molecular targets across the T.
cruzi genome that may have a lower number of copies per cell; however, this could affect the
sensitivity. Previously, some authors suggested the use of 18S, 24S, cytochrome oxidase II
(COII) or the spliced leader of miniexon gene for the molecular diagnosis of T. cruzi. However,
in an international consensus, these markers did not show satisfactory results in terms of sensi-
tivity [13]. New experiments would need to be performed with these molecular targets under a
ddPCR platform to determine their potential use. Additionally, in a recent analytical validation
report for T. cruzi, the kinetoplast (kDNA) showed interesting results in terms of sensitivity
that were improved for TcSTR [14]. We initially tested the kDNA reported by Ramı´rez et al.
2015 [14] and found oversaturation of the droplets preventing adequate discrimination of pos-
itive and negative droplets as with TcSTR. This might reflect the molecular nature of kDNA
(discoid DNA with minicircles and maxicircles). Therefore, we did not pursue this marker. In
Colombia, Trypanosoma rangeli is a frequent parasite and kDNA presents strong cross-
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reactivity with this protozoan [49]. Therefore, we concluded that TcSTR was the most suitable
approach to initiate the analytical validation of a ddPCR platform. However, maybe an opti-
mized primer or probe design could improve the analytical characteristics of ddPCR and addi-
tional experiments are needed to identify appropriate molecular candidates.
In several studies, ddPCR performed much better than qPCR for the detection of pathogen
DNA (for example, C. trachomatis, Salmonella, E. coli, C. jejuni, cytomegalovirus and HIV)
[20–24]. When applied to the detection of Plasmodium species, this tool was able to quantify
low parasitemia in subpatent infections, as well as determine Plasmodium species in cases of
low parasitemia [50]. In the case of Cryptosporidium, the precision of ddPCR was consistently
higher compared with qPCR but decreased as the DNA concentration decreased [27]. We did
not identify the same improvement in the detection of T. cruzi in blood samples after import-
ing the assay to the ddPCR platform. However, this corresponds a pioneer study towards the
establishment of an efficient protocol to employ ddPCR as a test to detect T. cruzi DNA in
blood samples. As mentioned before, novel targets and better primer design might potentially
improve the performance of the assay.
There are a number of limitations to our study. The samples used for the evaluation of clinical
performance did not incorporate samples from other clinical settings outside of Colombia. This is
important as the median parasitic load is higher in Colombian patients, and therefore the sensitiv-
ity may be reduced in patients from other regions. Also, the clinical stages, age and patient charac-
teristics could impact on the results of ddPCR. In our case, we observed that T. cruzi DNA could
be detected in acute and chronic patients by ddPCR with no statistical significance on the parasitic
load in terms of age or clinical stage. However, verification is required in a novel group of patients
including, for example, children and congenital cases. Additionally, the variation in TcSTR copy
number between DTUs and even within DTUs may cause the results to be variable in clinical set-
tings; a fixed copy number target would be preferable for the purposes of quantitation.
In conclusion, we report the first evaluation of the suitability of a ddPCR platform to detect
T. cruzi DNA in blood samples. The analytical and diagnostic performance of the ddPCR assay
evaluated here does not support its routine usage over qPCR. However, it shows several advan-
tages such as quantitation of DNA without the need for calibration curves thereby allowing for
exact and reference values to be obtained per sample (higher-order reference measurement
method) as has been suggested for various viral diseases. A range of samples from a larger geo-
graphical area should be tested and a future international consensus should be considered as
was conducted for qPCR to comprehensively determine the potential use of ddPCR to detect
and quantify T. cruzi in clinical samples.
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